Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D; RUTHERFORD-2 Investigators. Raal FJ, et al. Among authors: Bridges I. Lancet. 2015 Jan 24;385(9965):331-40. doi: 10.1016/S0140-6736(14)61399-4. Epub 2014 Oct 1. Lancet. 2015. PMID: 25282519 Clinical Trial.
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.
Hovingh GK, Raal FJ, Dent R, Stefanutti C, Descamps O, Masana L, Lira A, Bridges I, Coll B, Sullivan D. Hovingh GK, et al. Among authors: Bridges I. J Clin Lipidol. 2017 Nov-Dec;11(6):1448-1457. doi: 10.1016/j.jacl.2017.09.003. Epub 2017 Sep 22. J Clin Lipidol. 2017. PMID: 29066265 Clinical Trial.
Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, Bridges I, Worth GM, Dent R, Forbes CA, Deshpande S, Ross J, Kleijnen J, Stroes ESG. Toth PP, et al. Among authors: Bridges I. J Am Heart Assoc. 2017 Oct 2;6(10):e005367. doi: 10.1161/JAHA.116.005367. J Am Heart Assoc. 2017. PMID: 28971955 Free PMC article. Review.
Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.
Blom DJ, Djedjos CS, Monsalvo ML, Bridges I, Wasserman SM, Scott R, Roth E. Blom DJ, et al. Among authors: Bridges I. Circ Res. 2015 Sep 25;117(8):731-41. doi: 10.1161/CIRCRESAHA.115.307071. Epub 2015 Jul 30. Circ Res. 2015. PMID: 26228031 Clinical Trial.
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Raal F, et al. Among authors: Bridges I. Circulation. 2012 Nov 13;126(20):2408-17. doi: 10.1161/CIRCULATIONAHA.112.144055. Epub 2012 Nov 5. Circulation. 2012. PMID: 23129602 Clinical Trial.
Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study.
Petrov I, Dumitrescu A, Snejdrlova M, Zafrir B, Wożakowska-Kapłon B, Fabryova L, Pintarić H, Bridges I, Petkova R. Petrov I, et al. Among authors: Bridges I. Adv Ther. 2019 Mar;36(3):608-620. doi: 10.1007/s12325-019-0879-1. Epub 2019 Feb 13. Adv Ther. 2019. PMID: 30758746 Free PMC article. Clinical Trial.
19 results
Jump to page
Feedback